X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs CADILA HEALTHCARE - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA CADILA HEALTHCARE SANOFI INDIA/
CADILA HEALTHCARE
 
P/E (TTM) x 34.4 24.1 142.7% View Chart
P/BV x 6.9 6.0 114.1% View Chart
Dividend Yield % 1.3 0.8 168.0%  

Financials

 SANOFI INDIA   CADILA HEALTHCARE
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
CADILA HEALTHCARE
Mar-17
SANOFI INDIA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs4,560460 991.3%   
Low Rs4,400305 1,442.6%   
Sales per share (Unadj.) Rs1,028.592.1 1,116.6%  
Earnings per share (Unadj.) Rs129.014.8 870.4%  
Cash flow per share (Unadj.) Rs186.018.5 1,006.4%  
Dividends per share (Unadj.) Rs68.003.20 2,125.0%  
Dividend yield (eoy) %1.50.8 181.4%  
Book value per share (Unadj.) Rs753.668.0 1,108.5%  
Shares outstanding (eoy) m23.031,023.74 2.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.2 104.9%   
Avg P/E ratio x34.725.8 134.6%  
P/CF ratio (eoy) x24.120.7 116.4%  
Price / Book Value ratio x5.95.6 105.7%  
Dividend payout %52.721.6 244.1%   
Avg Mkt Cap Rs m103,174391,581 26.3%   
No. of employees `0003.616.9 21.5%   
Total wages/salary Rs m3,59215,002 23.9%   
Avg. sales/employee Rs Th6,537.75,594.5 116.9%   
Avg. wages/employee Rs Th991.4890.1 111.4%   
Avg. net profit/employee Rs Th819.8899.9 91.1%   
INCOME DATA
Net Sales Rs m23,68694,295 25.1%  
Other income Rs m7081,286 55.1%   
Total revenues Rs m24,39495,581 25.5%   
Gross profit Rs m5,28119,036 27.7%  
Depreciation Rs m1,3133,750 35.0%   
Interest Rs m15450 3.3%   
Profit before tax Rs m4,66116,122 28.9%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m1,6911,289 131.2%   
Profit after tax Rs m2,97015,168 19.6%  
Gross profit margin %22.320.2 110.4%  
Effective tax rate %36.38.0 453.8%   
Net profit margin %12.516.1 78.0%  
BALANCE SHEET DATA
Current assets Rs m15,67360,223 26.0%   
Current liabilities Rs m6,67853,058 12.6%   
Net working cap to sales %38.07.6 499.8%  
Current ratio x2.31.1 206.8%  
Inventory Days Days7670 108.8%  
Debtors Days Days2288 25.3%  
Net fixed assets Rs m8,09872,984 11.1%   
Share capital Rs m2301,024 22.5%   
"Free" reserves Rs m17,08868,576 24.9%   
Net worth Rs m17,35669,600 24.9%   
Long term debt Rs m024,684 0.0%   
Total assets Rs m25,400152,207 16.7%  
Interest coverage x311.736.8 846.5%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.90.6 150.5%   
Return on assets %11.810.3 114.5%  
Return on equity %17.121.8 78.5%  
Return on capital %26.917.9 150.2%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,14521,280 33.6%   
Fx outflow Rs m6,84610,874 63.0%   
Net fx Rs m29910,406 2.9%   
CASH FLOW
From Operations Rs m3,22613,495 23.9%  
From Investments Rs m-1,555-29,103 5.3%  
From Financial Activity Rs m-1,81823,158 -7.9%  
Net Cashflow Rs m-1477,556 -1.9%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 8.3 173.5%  
FIIs % 14.6 5.9 247.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 11.0 95.5%  
Shareholders   15,184 44,069 34.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   AJANTA PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jun 21, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - WOCKHARDT LTD. COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS